A Pharma Giant Built For The Long Haul

I was sitting in my 1946 Ercoupe at the Nevada airfield last weekend, waiting for clearance to take off for a quick joy flight, when my phone buzzed with a text from a longtime Concierge client. “What’s the deal with AbbVie (ABBV)?” he wanted to know. “Is it worth adding to my portfolio now?” The […]

A Buy Write Primer

With both market technical and fundamentals going to hell in a handbasket, it’s time to take a refresher course on “Buy Writes.” I have advised followers to dump the positions they are dating and only keep the ones they are married to. It’s worth enduring a 30% drawdown in a high-quality name to capture a […]